Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

Morphea Clinical Trial

Official title: Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

Status Completed

Clinical Trial Summary

This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.

Clinical Trial Description

A Phase 2, pilot, proof-of-concept, open label, single arm prospective study to assess the safety, tolerability and efficacy of using crisaborole 2% ointment for adult morphea. Patients identified by their physician, nurse, or other member of their clinical care team as meeting criteria for the study will be asked to apply crisaborole 2% ointment, twice daily, on affected plaques for 12 weeks. A 4 mm skin punch biopsy will be performed at baseline and at 12 weeks, on the same affected plaque. Dermal thickness will be measured and compared before and at the end of treatment. Patients will have a clinical assessment at baseline and at weeks 4, 8 and 12. After week 12, patients who need further treatment will undergo standard of care treatment as determined by their primary dermatologist. Physician and patient reported assessment and skin imaging will be performed at baseline, week 4, 8 and 12, and at week 20. Photography will also be performed at baseline and week 12. An optional post treatment follow-up will be performed at week 20. Medication will be provided free of charge by Pfizer, as part of the grant that is funding this study. These will be dispensed by the study group at baseline and during the subsequent clinic visits. ;

Related Conditions & MeSH terms

• Morphea
• Scleroderma, Localized

• NCT number: NCT03351114
• Study type: Interventional
• Source: Duke University
• Status: Completed
• Phase: Phase 2
• Start date: September 1, 2018
• Completion date: March 10, 2020